International Society for the Study of Women's Sexual Health

Flibanserin recommended for approval by the FDA Advisory Committee Panel

Dear ISSWSH members,
It is with great excitement that I share the announcement that flibanserin, a drug for hypoactive sexual desire disorder (HSDD) developed by Sprout Pharmaceuticals, was recommended for approval by the FDA Advisory Committee Panel on June 4, 2015.

This event opens the door for the first treatment for women suffering from HSDD, but more importantly sends the message that the FDA is now willing to entertain new drug applications from other companies. We are optimistic that this occurrence will instigate more research and eventually other therapeutic options. We also offer deep gratitude to many of our members who played a key role in this decision by voting as members of the FDA Advisory Panel, speaking as presenters on behalf of the sponsor, providing testimony during the Open Public Hearing, and caring for patients who also spoke at the Hearing.  

As a multidisciplinary, scientific organization dedicated to research, clinical practice, and education, we are poised to develop and disseminate clinical practice guidelines regarding screening, diagnosis, and management strategies. Through our robust infrastructure of educational programs, we will ensure appropriate, safe, and selective treatment of HSDD with flibanserin when final approval comes.

Most sincerely,
Sharon J. Parish, MD, IF
ISSWSH President, 2014-2016

Save the Date

ISSWSH Fall Course 2019
November 14-16, 2019   141 days left
DoubleTree Hilton Hotel, Scottsdale, AZ - USA
Read more...

ISSWSH Annual Meeting 2020
March 5-8, 2020   253 days left
Renaissance Orlando at Seaworld, Orlando, FL, USA

ISSWSH Annual Meeting 2021
March 4-7, 2021   617 days left
Renaissance Dallas Hotel, Dallas, TX, USA

Latest Tweets

FDA slow to implement regulations on Vaginal Mesh, increasing public apprehension in use of devices for health bene… https://t.co/uAgdBlNDS1 ISSWSH
FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women https://t.co/1iBr8jmmOE ISSWSH
“I realize that there are a lot of critics,” she said in 1983, “but I’ve found out that nine times out of 10 they h… https://t.co/oAPG388zrw ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow us on Twitter!